- Home
- CRIS vs DRCT Comparison
CRIS vs DRCT Comparison
Compare CRIS & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | DRCT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 8.9M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CRIS | DRCT |
|---|---|---|
| Price | $1.04 | $0.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.50 | $6.00 |
| AVG Volume (30 Days) | 114.9K | ★ 30.5M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $11,650,000.00 | ★ $35,369,000.00 |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $7.86 | $25.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $1.02 | $0.05 |
| 52 Week High | $4.50 | $3.30 |
Technical Indicators
Market Signals| Indicator | CRIS | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 35.03 | 23.61 |
| Support Level | $1.02 | $0.05 |
| Resistance Level | $1.14 | $0.08 |
| Average True Range (ATR) | 0.08 | 0.01 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 5.14 | 9.51 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.